Abstract:Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson’s and Alzheimer’s. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer’s dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca2+ overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer’s disease.

β-Amyloids and Immune Responses Associated with Alzheimer's Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

The role of the immune system in Alzheimer's disease

Immune attack: the role of inflammation in Alzheimer disease

Structural biology of cell surface receptors implicated in Alzheimer’s disease

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Altered T cell reactivity to β-amyloid-related antigens in early Alzheimer's disease

The role of the immune system in Alzheimer’s disease

The association of microbial infection and adaptive immune cell activation in Alzheimer's disease

Dissecting the immune response of CD4 + T cells in Alzheimer's disease

Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis

Intracellular A beta and its Pathological Role in Alzheimer's Disease: Lessons from the Cellular to Animal Model

Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer's disease

The neuroimmune axis of Alzheimer's disease

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules

The Role of Intracellular Amyloid Beta in Alzheimer'S Disease

Interactions Between Amyloid Β Peptide and Lipid Membranes.

Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches

Genomics of Alzheimer’s disease implicates the innate and adaptive immune systems

Amyloid, Tau, Pathogen Infection and Antimicrobial Protection in Alzheimer’s Disease –conformist, Nonconformist, and Realistic Prospects for AD Pathogenesis

Mechanistic insights into the role of amyloid-β in innate immunity